Research
Advanced Medical Research Center
Advanced Medical Research Center（SENTANKEN）conducts basic studies aimed at overcoming cancer and lifestyle diseases and translational researches which applies the scientific finding to clinical medicine. It has three omics centers – genomics, proteomics, cellomics –and a biobank, collaborates within YCU and with other research institutions, and promote translational researches. AMRC is also involved in a number of R&D, working with the industry. Our goal is to make our research findings available to the society without delay.
Outline, Structure & Function of the Advanced Medical Research Center >
Outline, Structure & Function of the Advanced Medical Research Center >
RESEARCH > ADVANCED MEDICAL RESEARCH CENTER
Message from the Director
The Advanced Medical Research Center (SENTANKEN) of Yokohama City University(YCU) was established in 2006. The assignment of SENTANKEN is to facilitate advanced medical research associated with diseases such as cancer and lifestyle-related diseases. SENTANKEN is focused on basic researches in the field of genomics, proteomics and cellomics, as well as translational researches, which can fill the gap between basic and clinical researches, and promotes not only intramural collaboration but also between government, industry and academia.
Our goal is to make an attractive YCU that can contribute to the community by delivering the research outcomes of our basic and clinical researches promptly to the citizens of Yokohama and by connecting these activities for the revitalization of industries in Yokohama.
Our goal is to make an attractive YCU that can contribute to the community by delivering the research outcomes of our basic and clinical researches promptly to the citizens of Yokohama and by connecting these activities for the revitalization of industries in Yokohama.
Professor Atsushi Nakajima
Director, Advanced Medical Research Center
Departments & Divisions
Department of Research & Development
Developing new methods for prevention, diagnosis and treatment of socially significant illnesses such as cancer and lifestyle-related diseases.
Developing new methods for prevention, diagnosis and treatment of socially significant illnesses such as cancer and lifestyle-related diseases.
Department of Research Support & Coordination
The AMRC has seven research laboratories which can develop cutting-edge joint research activities at every level - from genomics to proteomics, to celllomics - and use secimens of excellent quality as medical resources.
The AMRC has seven research laboratories which can develop cutting-edge joint research activities at every level - from genomics to proteomics, to celllomics - and use secimens of excellent quality as medical resources.
Biobank Division
To ensure a timely supply of human tissue specimens to researchers for the purpose of Translational Research, the Biobank Division stores and manages tissue samples and clinical information provided by patients at the University Hospital.
To ensure a timely supply of human tissue specimens to researchers for the purpose of Translational Research, the Biobank Division stores and manages tissue samples and clinical information provided by patients at the University Hospital.
Research News
2022-03-23
On Saturday, August 21, 2021, the 23rd Comparative Glycomics Research Meeting was held at the Training Center of Sail Training Ship NIPPON MARU (Yokohama, Japan). A total of 50 participants onsite and online, including participants from Japan, the United States of America, Belgium, and China, were connected for eight presentations and discussions.
2021-12-02
It remains unclear which sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are most effective for preventing cardiovascular and renal events in type 2 diabetes mellitus (T2DM) patients, depending on the presence of albuminuria. We conducted a network meta-analysis to compare the efficacy of these two drug classes in T2DM patients with/without albuminuria.
2021-12-02
Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients.
Contact info
sentan@yokohama-cu.ac.jp